Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement
In this real-world European cohort, lebrikizumab demonstrated sustained effectiveness and a favorable safety profile over 52 weeks, including in patients with head and neck involvement, supporting its long-term use in routine clinical practice.
Authors
- Marco Valenti (ORCID: https://orcid.org/0000-0001-9043-3456)
- Paolo Calzari (ORCID: https://orcid.org/0000-0001-7690-7221)
- Luciano Ibba (ORCID: https://orcid.org/0000-0002-7876-4866)
- Martina Zussino (ORCID: https://orcid.org/0000-0003-0999-9183)
- Silvia Mariel Ferrucci (ORCID: https://orcid.org/0000-0002-6734-1366)
- Alessandra Narcisi (ORCID: https://orcid.org/0000-0002-1938-8581)
- S. Di Giulio (ORCID: https://orcid.org/0009-0001-3780-5318)
- Luigi Gargiulo
- Gianluca Avallone
- Matteo Bianco
- Angelo Valerio Marzano
- Antonio Costanzo
Institutions
- Humanitas University (IT)
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s13555-026-01726-w
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00